For therapeutic-grade manufacture of exosomes it’s critical to develop a scalable purification workflow. Ultracentrifugation and density gradient separation are suitable for characterization. However, both suffer from poor yields, scalability issues, and potential structural damage to exosomes.
This study describes a comprehensive purification workflow for both research and manufacturing involving depth filtration, Benzonase treatment for DNA/RNA degradation, tangential flow filtration for concentration, and either size-exclusion chromatography (SEC) using Cytiva superSEC resin or multimodal chromatography (MMC) with Capto Core 700 resin. Both chromatography options allow for scale-up and packing into large columns.
Demonstrated on exosomes from three cell lines, this process ― validated through collaboration with VivaZome Therapeutics Pty Ltd and Cytiva R&D ― provides efficient, high-yield production.
If you want to know more about Cytiva(TM) superSEC resin, please visit our website" and the following link:
https://www.cytivalifesciences.com/en/us/shop/chromatography/resins/size-exclusion/cytiva-supersec-resin-p-43921
